Usefulness of Whole-Body Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Patients with Neurofibromatosis Type 1: A Systematic Review
Open Access
- 9 September 2012
- journal article
- review article
- Published by Hindawi Limited in Radiology Research and Practice
- Vol. 2012, 1-9
Abstract
Aim. To systematically review the role of positron emission tomography (PET) with fluorine-18-fluorodeoxyglucose (FDG) in patients with neurofibromatosis type 1 (NF1).Methods. A comprehensive literature search of published studies regarding FDG-PET and PET/CT in patients with NF1 was performed. No beginning date limit and language restriction were used; the search was updated until December 2011. Only those studies or subsets in studies including whole-body FDG-PET or PET/CT scans performed in patients with NF1 were included.Results. We identified 12 studies including 352 NF1 patients. Qualitative evaluation was performed in about half of the studies and semiquantitative analysis, mainly based on different values of SUV cutoff, in the others. Most of the studies evaluated the role of FDG-PET for differentiating benign from malignant peripheral nerve sheath tumors (MPNSTs). Malignant lesions were detected with a sensitivity ranging between 100% and 89%, but with lower specificity, ranging between 100% and 72%. Moreover, FDG-PET seems to be an important imaging modality for predicting the progression to MPNST and the outcome in patients with MPNST. Two studies evaluated the role of FDG-PET in pediatric patients with NF1.Conclusions. FDG-PET and PET/CT are useful methods to identify malignant change in neurogenic tumors in NF1 and to discriminate malignant from benign neurogenic lesions.Keywords
This publication has 20 references indexed in Scilit:
- Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benignCancer, 2009
- POTENTIAL ROLE OF 18FLUORODEOXYGLUCOSE–POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN DIFFERENTIATING BENIGN NEUROFIBROMA FROM MALIGNANT PERIPHERAL NERVE SHEATH TUMOR ASSOCIATED WITH NEUROFIBROMATOSIS 1Neurosurgery, 2009
- Utilization of positron emission tomography in the management of patients with sarcomaCurrent Opinion in Oncology, 2009
- [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical studyAnnals of Oncology, 2007
- Value of PET in the Assessment of Patients with Neurofibromatosis Type 1American Journal of Roentgenology, 2007
- Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspectiveThe Lancet Neurology, 2007
- Neurofibromatosis 1European Journal of Human Genetics, 2006
- Clinical Manifestations and Management of Neurofibromatosis Type 1Seminars in Pediatric Neurology, 2006
- Pediatric Malignant Peripheral Nerve Sheath Tumor: The Italian and German Soft Tissue Sarcoma Cooperative GroupJournal of Clinical Oncology, 2005
- Malignant peripheral nerve sheath tumours in neurofibromatosis 1Journal of Medical Genetics, 2002